A role for the PPARγ in cancer therapy

PPAR Research

Volumn , Issue , 2008, Pages

  Campbell, Moray J ^a   Carlberg, Carsten ^b,c   Koeffler, H Phillip ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANAEROBIC GLYCOLYSIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CANCER THERAPY; CATABOLISM; CELL DIFFERENTIATION; CELL ENERGY; CELL GROWTH; CELL RENEWAL; CHEMOPROPHYLAXIS; COLON CANCER; DIET; HUMAN; LEUKEMIA; LYMPHOMA; PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION;

EID: 45249097593     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/314974     Document Type: Review

References (225)

1. Tontonoz P., Graves R. A., Budavari A. I., Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR γ and RXR α Nucleic Acids Research 1994 22 25 5628 5634
2. Tontonoz P., Hu E., Spiegelman B. M., Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor Cell 1994 79 7 1147 1156
3. Fajas L., Fruchart J.-C., Auwerx J.
4. Takano H., Hasegawa H., Nagai T., Komuro I.
5. Glass C. K.
6. Heikkinen S., Auwerx J.
7. Staels B.
8. Imai T., Takakuwa R., Marchand S., Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse Proceedings of the National Academy of Sciences of the United States of America 2004 101 13 4543 4547
9. Gampe R. T. Jr., Montana V. G., Lambert M. H., Asymmetry in the PPAR γ /RXR α crystal structure reveals the molecular basis of heterodimerization among nuclear receptors Molecular Cell 2000 5 3 545 555
10. Li J., Wang J., Wang J., Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3 The EMBO Journal 2000 19 16 4342 4350
11. Yoon H.-G., Chan D. W., Huang Z.-Q., Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1 The EMBO Journal 2003 22 6 1336 1346
12. Alenghat T., Yu J., Lazar M. A.
13. Picard F., Kurtev M., Chung N., Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR- γ Nature 2004 429 6993 771 776
14. Yu C., Markan K., Temple K. A., Deplewski D., Brady M. J., Cohen R. N., The nuclear receptor corepressors N-CoR and SMRT decrease PPAR γ transcriptional activity and repress 3t3-l1 adipogenesis Journal of Biological Chemistry 2005 28 1 295 302
15. Takada I., Mihara M., Suzawa M., A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR- γ transactivation Nature Cell Biology 2007 9 11 1273 1285
16. Ge K.
17. Ge K., Guermah M., Yuan C.-X., Transcription coactivator TRAP220 is required for PPAR γ 2-stimulated adipogenesis Nature 2002 417 6888 563 567
18. Puigserver P., Adelmant G., Wu Z., Activation of PPAR γ coactivator-1 through transcription factor docking Science 1999 286 5443 1368 1371
19. Wallberg A. E., Yamamura S., Malik S., Spiegelman B. M., Roeder R. G.
20. Liu C., Li S., Liu T., Borjigin J., Lin J. D.
21. Zhang Y., Ba Y., Liu C., PGC-1 α induces apoptosis in human epithelial ovarian cancer cells through a PPAR γ -dependent pathway Cell Research 2007 17 4 363 373
22. Yadav N., Cheng D., Richard S., CARM1 promotes adipocyte differentiation by coactivating PPAR γ EMBO Reports 2008 9 2 193 198
23. Métivier R.
24. Reid G., Hübner M. R., Métivier R., Cyclic, proteasome-mediated turnover of unliganded and liganded ER α on responsive promoters is an integral feature of estrogen signaling Molecular Cell 2003 11 3 695 707
25. Väisänen S., Dunlop T. W., Sinkkonen L., Frank C., Carlberg C.
26. Altmann R., Hausmann M., Spöttl T., 13-Oxo-ODE is an endogenous ligand for PPAR γ in human colonic epithelial cells Biochemical Pharmacology 2007 74 4 612 622
27. Subbarayan V., Krieg P., Hsi L. C., 15-lipoxygenase-2 gene regulation by its product 15- (S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor γ Oncogene 2006 25 44 6015 6025
28. Subbarayan V., Xu X.-C., Kim J., Inverse relationship between 15-lipoxygenase-2 and PPAR- γ gene expression in normal epithelia compared with tumor epithelia Neoplasia 2005 7 3 280 293
29. Nagy L., Tontonoz P., Alvarez J. G. A., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ Cell 1998 93 2 229 240
30. Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M., 15-deoxy- Δ12,14 -prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ Cell 1995 83 5 803 812
31. Krey G., Braissant O., L'Horset F., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Molecular Endocrinology 1997 11 6 779 791
32. Ng V. Y., Huang Y., Reddy L. M., Falck J. R., Lin E. T., Kroetz D. L.
33. Shappell S. B., Gupta R. A., Manning S., 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells Cancer Research 2001 61 2 497 503
34. Chou W.-L., Chuang L.-M., Chou C.-C., Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor γ activation Journal of Biological Chemistry 2007 282 25 18162 18172
35. Sabichi A. L., Subbarayan V., Llansa N., Lippman S. M., Menter D. G.
36. Mora F. D., Jones D. K., Desai P. V., Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor- γ (PPAR γ): the marine sponge metabolite psammaplin A activates PPAR γ and induces apoptosis in human breast tumor cells Journal of Natural Products 2006 69 4 547 552
37. Falcetti E., Flavell D. M., Staels B., Tinker A., Haworth S. G., Clapp L. H.
38. Usui S., Fujieda H., Suzuki T., Synthesis and evaluation of 2-nonylaminopyridine derivatives as PPAR ligands Chemical & Pharmaceutical Bulletin 2007 55 7 1053 1059
39. Yamaguchi K., Lee S.-H., Eling T. E., Baek S. J., A novel peroxisome proliferator-activated receptor γ ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells Molecular Cancer Therapeutics 2006 5 1352 1361
40. Lu I.-L., Huang C.-F., Peng Y.-H., Structure-based drug design of a novel family of PPAR γ partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities Journal of Medicinal Chemistry 2006 49 9 2703 2712
41. Fujimura T.
42. Mahindroo N., Wang C.-C., Liao C.-C., Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies Journal of Medicinal Chemistry 2006 49 3 1212 1216
43. Burgermeister E., Schnoebelen A., Flament A., A novel partial agonist of peroxisome proliferator-activated receptor- γ (PPAR γ) recruits PPAR γ -coactivator-1 α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro Molecular Endocrinology 2006 20 4 809 830
44. Tomita T., Kakiuchi Y., Tsao P. S., THR0921, a novel peroxisome proliferator-activated receptor γ agonist, reduces the severity of collagen-induced arthritis Arthritis Research & Therapy 2006 8 1, article R7
45. Itoh T., Murota I., Yoshikai K., Yamada S., Yamamoto K.
46. Salt D. W., Hudson B. D., Banting L., Ellis M. J.
47. Shiraki T., Kamiya N., Shiki S., Kodama T. S., Kakizuka A., Jingami H.
48. Östberg T., Svensson S., Selén G., A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects Journal of Biological Chemistry 2004 279 39 41124 41130
49. Cho M. C., Lee H. S., Kim J. H., A simple ELISA for screening ligands of peroxisome proliferator-activated receptor γ Journal of Biochemistry and Molecular Biology 2003 36 2 207 213
50. Takagi T., Naito Y.
51. Baek S. J., Wilson L. C., Hsi L. C., Eling T. E.
52. Einstein M., Akiyama T., Castriota G., The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities Molecular Pharmacology 2008 73 62 74
53. Fujimura T., Sakuma H., Konishi S., FK614, a novel peroxisome proliferator-activated receptor γ modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators Journal of Pharmacological Sciences 2005 99 4 342 352
54. Shiraki T., Kodama T. S., Jingami H., Kamiya N.
55. Elbrecht A., Chen Y., Adams A., L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ. The role of Cys313 in ligand binding Journal of Biological Chemistry 1999 274 12 7913 7922
56. Zhang B.
57. Pourcet B., Fruchart J.-C., Staels B.
58. Molnár F., Matilainen M., Carlberg C.
59. Sandri M., Lin J., Handschin C., PGC-1 α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription Proceedings of the National Academy of Sciences of the United States of America 2006 103 44 16260 16265
60. Handschin C., Spiegelman B. M., Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism Endocrine Reviews 2006 27 7 728 735
61. Sano M., Tokudome S., Shimizu N., Intramolecular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor γ coactivator 1 α Journal of Biological Chemistry 2007 282 35 25970 25980
62. Yamashita D., Yamaguchi T., Shimizu M., Nakata N., Hirose F., Osumi T.
63. Pascual G., Fong A. L., Ogawa S., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR- γ Nature 2005 437 7059 759 763
64. Choi S. J., Chung S. S., Rho E. J., Negative modulation of RXR α transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by sumo-specific protease susp1 Journal of Biological Chemistry 2006 281 41 30669 30677
65. Burgermeister E., Seger R., MAPK kinases as nucleo-cytoplasmic shuttles for PPAR γ Cell Cycle 2007 6 13 1539 1548
66. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., Seger R., Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ Molecular and Cellular Biology 2007 27 3 803 817
67. Yin R., Dong Y. G., Li H. L., PPAR γ phosphorylation mediated by JNK MAPK: a potential role in macrophage-derived foam cell formation Acta Pharmacologica Sinica 2006 27 9 1146 1152
68. Misra P., Owuor E. D., Li W., Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP). Stimulation of transcriptional regulation by mitogen-activated protein kinase Journal of Biological Chemistry 2002 277 50 48745 48754
69. Bookout A. L., Jeong Y., Downes M., Yu R. T., Evans R. M., Mangelsdorf D. J.
70. Yang X., Downes M., Yu R. T., Nuclear receptor expression links the circadian clock to metabolism Cell 2006 126 4 801 810
71. Perera R. J., Marcusson E. G., Koo S., Identification of novel PPAR γ target genes in primary human adipocytes Gene 2006 369 90 99
72. Hodgkinson C. P.
73. Vignati S., Albertini V., Rinaldi A., Cellular and molecular consequences of peroxisome proliferator-activated receptor- γ activation in ovarian cancer cells Neoplasia 2006 8 10 851 861
74. Shen Z. N., Nishida K., Doi H., Suppression of chondrosarcoma cells by 15-deoxy- Δ12,14 -prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21 Biochemical and Biophysical Research Communications 2005 328 2 375 382
75. Suzuki T., Hayashi S., Miki Y., Peroxisome proliferator-activated receptor γ in human breast carcinoma: a modulator of estrogenic actions Endocrine-Related Cancer 2006 13 1 233 250
76. Lecka-Czernik B., Ackert-Bicknell C., Adamo M. L., Activation of peroxisome proliferator-activated receptor γ (PPAR γ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo Endocrinology 2007 148 2 903 911
77. Degenhardt T., Matilainen M., Herzig K.-H., Dunlop T. W., Carlberg C.
78. Gupta R. A., Brockman J. A., Sarraf P., Willson T. M., DuBois R. N.
79. Zandbergen F., Mandard S., Escher P., The G0/G1 switch gene 2 is a novel PPAR target gene Biochemical Journal 2005 392 2 313 324
80. Bruemmer D., Yin F., Liu J., Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor γ in vascular smooth muscle cells Circulation Research 2003 93 4 e38 e47
81. Han C., Demetris A. J., Michalopoulos G. K., Zhan Q., Shelhamer J. H., Wu T.
82. Yasui Y., Hosokawa M., Sahara T., Bitter gourd seed fatty acid rich in 9 c,11 t,13 t -conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPAR γ in human colon cancer Caco-2 cells Prostaglandins, Leukotrienes and Essential Fatty Acids 2005 73 2 113 119
83. Nielsen R., Grøntved L., Stunnenberg H. G., Mandrup S.
84. Szatmari I., Pap A., Ruhl R., PPAR γ controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells Journal of Experimental Medicine 2006 203 10 2351 2362
85. Dai X., Sayama K., Shirakata Y., PPAR γ is an important transcription factor in 1 α,25-dihydroxyvitamin D3-induced involucrin expression Journal of Dermatological Science 2008 50 1 53 60
86. Ziouzenkova O., Plutzky J.
87. Carroll J. S., Meyer C. A., Song J., Genome-wide analysis of estrogen receptor binding sites Nature Genetics 2006 38 11 1289 1297
88. Heinäniemi M., Uski J. O., Degenhardt T., Carlberg C., Meta-analysis of primary target genes of peroxisome proliferator-activated receptors Genome Biology 2007 8 7, article R147
89. Hanahan D., Weinberg R. A., The hallmarks of cancer Cell 2000 100 1 57 70
90. Shackleton M., Vaillant F., Simpson K. J., Generation of a functional mammary gland from a single stem cell Nature 2006 439 7072 84 88
91. Stingl J., Eirew P., Ricketson I., Purification and unique properties of mammary epithelial stem cells Nature 2006 439 7079 993 997
92. Richardson G. D., Robson C. N., Lang S. H., Neal D. E., Maitland N. J., Collins A. T.
93. Rizzo S., Attard G., Hudson D. L.
94. Barker N., van Es J. H., Kuipers J., Identification of stem cells in small intestine and colon by marker gene Lgr5 Nature 2007 449 7165 1003 1007
95. Kiel M. J., He S., Ashkenazi R., Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU Nature 2007 449 7159 238 242
96. Lansdorp P. M., Immortal strands? Give me a break Cell 2007 129 7 1244 1247
97. Conboy M. J., Karasov A. O., Rando T. A., High incidence of non-random template strand segregation and asymmetric fate determination in dividing stem cells and their progeny PLoS Biology 2007 5 5 e102
98. Shinin V., Gayraud-Morel B., Gomès D., Tajbakhsh S.
99. Karpowicz P.
100. Roberts S. A.
101. Rambhatla L., Ram-Mohan S., Cheng J. J., Sherley J. L.
102. Cairns J., Mutation selection and the natural history of cancer Nature 1975 255 5505 197 200
103. Potten C. S., Hume W. J., Reid P., Cairns J., The segregation of DNA in epithelial stem cells Cell 1978 15 3 899 906
104. Al-Hajj M., Becker M. W., Wicha M., Weissman I., Clarke M. F.
105. Setoguchi T., Taga T., Kondo T.
106. Collins A. T.
107. O'Brien C. A., Pollett A., Gallinger S., Dick J. E.
108. Wicha M. S.
109. Tontonoz P., Singer S., Forman B. M., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor Proceedings of the National Academy of Sciences of the United States of America 1997 94 1 237 241
110. Elstner E., Müller C., Koshizuka K., Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8806 8811
111. Mueller E., Sarraf P., Tontonoz P., Terminal differentiation of human breast cancer through PPAR γ Molecular Cell 1998 1 3 465 470
112. Butler R., Mitchell S. H., Tindall D. J., Young C. Y., Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy- Δ12,14 -prostaglandin J2 Cell Growth & Differentiation 2000 11 1 49 61
113. Jiang W. G., Redfern A., Bryce R. P., Mansel R. E., Peroxisome proliferator activated receptor- γ (PPAR- γ) mediates the action of gamma linolenic acid in breast cancer cells Prostaglandins, Leukotrienes and Essential Fatty Acids 2000 62 2 119 127
114. Mehta R. G.
115. Mueller E., Smith M., Sarraf P., Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10990 10995
116. Nakashiro K.-I., Hayashi Y., Kita A., Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells American Journal of Pathology 2001 159 2 591 597
117. Smith M. R., Kantoff P. W., Peroxisome proliferator-activated receptor γ (PPAR γ) as a novel target for prostate cancer Investigational New Drugs 2002 20 2 195 200
118. Jackson L., Wahli W., Michalik L., Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer Gut 2003 52 9 1317 1322
119. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., Safe S., Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells Cancer Research 2003 63 5 958 964
120. Xu Y., Iyengar S., Roberts R. L., Shappell S. B., Peehl D. M.
121. Yoshimura R.
122. Lu J.
123. Radhakrishnan S. K., Gartel A. L.
124. Cesario R. M., Stone J., Yen W. C., Bissonnette R. P., Lamph W. W., Differentiation and growth inhibition mediated via the RXR:PPAR γ heterodimer in colon cancer Cancer Letters 2006 240 2 225 233
125. Kassouf W., Chintharlapalli S., Abdelrahim M., Nelkin G., Safe S., Kamat A. M., Inhibition of bladder tumor growth by 1,1-bis(3′ -indolyl)-1-(p -substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor γ agonists Cancer Research 2006 66 1 412 418
126. Lee C. J., Han J. S., Seo C. Y., Pioglitazone, a synthetic ligand for PPAR γ, induces apoptosis in RB-deficient human colorectal cancer cells Apoptosis 2006 11 3 401 411
127. Li M. Y., Lee T. W., Yim A. P., Chen G. G., Function of PPAR γ and its ligands in lung cancer Critical Reviews in Clinical Laboratory Sciences 2006 43 183 202
128. Nakata S., Yoshida T., Shiraishi T., 15-deoxy- Δ12,14 -prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPAR γ and potentiates trail-induced apoptosis Molecular Cancer Therapeutics 2006 5 7 1827 1835
129. Núñez N. P., Liu H., Meadows G. G.
130. Bocca C., Bozzo F., Francica S., Colombatto S., Miglietta A., Involvement of PPAR γ and E-cadherin/ β -catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF-7 cells International Journal of Cancer 2007 121 2 248 256
131. Kim K. Y., Ahn J. H., Cheon H. G., Apoptotic action of peroxisome proliferator-activated receptor- γ activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation Molecular Pharmacology 2007 72 3 674 685
132. Lin M. S., Chen W. C., Bai X., Wang Y. D., Activation of peroxisome proliferator-activated receptor γ inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer Journal of Digestive Diseases 2007 8 2 82 88
133. Nam D.-H., Ramachandran S., Song D.-K., Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR γ ligand ciglitizone Molecular Human Reproduction 2007 13 11 829 836
134. Shigeto T., Yokoyama Y., Xin B., Mizunuma H., Peroxisome proliferator-activated receptor α and γ ligands inhibit the growth of human ovarian cancer Oncology Reports 2007 18 4 833 840
135. Su Y., Vanderlaag K., Ireland C., 1,1-bis(3′ -indolyl)-1-(p -biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice Breast Cancer Research 2007 9 4, article R56
136. Yang Y.-C.
137. Servidei T., Morosetti R., Ferlini C., The cellular response to PPAR γ ligands is related to the phenotype of neuroblastoma cell lines Oncology Research 2004 14 7-8 345 354
138. Morosetti R., Servidei T., Mirabella M., The PPAR γ ligands PG J2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines International Journal of Oncology 2004 25 2 493 502
139. Konopleva M., Elstner E., McQueen T. J., Peroxisome proliferator- activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias Molecular Cancer Therapeutics 2004 3 10 1249 1262
140. Lee Y.-R., Yu H.-N., Noh E.-M., Peroxisome proliferator-activated receptor γ and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells International Journal of Hematology 2007 85 3 231 237
141. Saez E., Tontonoz P., Nelson M. C., Activators of the nuclear receptor PPAR γ enhance colon polyp formation Nature Medicine 1998 4 9 1058 1061
142. McAlpine C. A., Barak Y., Matise I., Cormier R. T.
143. Wei S., Lin L.-F., Yang C.-C., Thiazolidinediones modulate the expression of β -catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor γ Molecular Pharmacology 2007 72 3 725 733
144. Weng J.-R., Chen C.-Y., Pinzone J. J., Ringel M. D., Chen C.-S.
145. Huang J.-W., Shiau C.-W., Yang Y.-T., Peroxisome proliferator-activated receptor γ -independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells Molecular Pharmacology 2005 67 4 1342 1348
146. Jansson E. C., Are A., Greicius G., The Wnt/ β -catenin signaling pathway targets PPAR γ activity in colon cancer cells Proceedings of the National Academy of Sciences of the United States of America 2005 102 5 1460 1465
147. Posch M. G.
148. Slattery M. L.
149. Bull A. W.
150. Chintharlapalli S., Papineni S., Safe S.
151. Yoshizumi T., Ohta T., Ninomiya I., Thiazolidinedione, a peroxisome proliferator-activated receptor- γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects International Journal of Oncology 2004 25 3 631 639
152. Yamazaki K., Shimizu M.
153. Chang A. J., Song D. H., Wolfe M. M.
154. de Lau W., Barker N., Clevers H.
155. Suh N., Wang Y., Williams C. R., A new ligand for the peroxisome proliferator-activated receptor- γ (PPAR- γ), GW7845, inhibits rat mammary carcinogenesis Cancer Research 1999 59 22 5671 5673
156. Nicol C. J., Yoon M., Ward J. M., PPAR γ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis Carcinogenesis 2004 25 9 1747 1755
157. Saez E., Rosenfeld J., Livolsi A., PPAR γ signaling exacerbates mammary gland tumor development Genes & Development 2004 18 5 528 540
158. Kilgore M. W.
159. Elstner E., Williamson E. A., Zang C., Novel therapeutic approach: ligands for PPAR γ and retinoid receptors induce apoptosis in Bcl-2-positive human breast cancer cells Breast Cancer Research and Treatment 2002 74 2 155 165
160. Crowe D. L., Chandraratna R. A., A retinoid X receptor (RXR)-selective retinoid reveals that RXR- α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands Breast Cancer Research 2004 6 5 R546 R555
161. Seargent J. M., Yates E. A., Gill J. H.
162. Jarrar M. H., Baranova A.
163. Mody M., Dharker N., Bloomston M., Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor- α, CH11 and CYC202 Endocrine-Related Cancer 2007 14 2 305 315
164. James S. Y., Lin F., Kolluri S. K., Dawson M. I., Zhang X.-K.
165. Sun H., Berquin I. M., Edwards I. J.
166. Kim H.-J., Kim J.-Y., Meng Z., 15-deoxy- Δ12,14 -prostaglandin J2 inhibits transcriptional activity of estrogen receptor- α via covalent modification of DNA-binding domain Cancer Research 2007 67 6 2595 2602
167. Papadaki I., Mylona E., Giannopoulou I., Markaki S., Keramopoulos A., Nakopoulou L.
168. Burstein H. J.
169. Goldblatt M. W., Properties of human seminal plasma Journal of Physiology 1935 84 2 208 218
170. Kim J., Yang P., Suraokar M., Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products Cancer Research 2005 65 14 6189 6198
171. Kubota T., Koshizuka K., Williamson E. A., Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Research 1998 58 15 3344 3352
172. Shiau C.-W., Yang C.-C., Kulp S. K., Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR γ Cancer Research 2005 65 4 1561 1569
173. Yang C.-C., Ku C.-Y., Wei S., Peroxisome proliferator-activated receptor γ -independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells Molecular Pharmacology 2006 69 5 1564 1570
174. Saez E., Olson P., Evans R. M.
175. Asou H., Verbeek W., Williamson E., Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor γ, and retinoids International Journal of Oncology 1999 15 5 1027 1031
176. Kumagai T.
177. Wang L. H.
178. Liu H., Zang C., Fenner M. H., Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPAR α / γ ligand TZD18 Blood 2006 107 9 3683 3692
179. Bouancheau D., Jarry A., Mottier S., Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor γ, in colorectal adenocarcinoma Oncology Reports 2007 18 2 489 495
180. Wang X., Southard R. C., Kilgore M. W.
181. Subbarayan V., Sabichi A. L., Kim J., Differential peroxisome proliferator-activated receptor- γ isoform expression and agonist effects in normal and malignant prostate cells Cancer Epidemiology Biomarkers & Prevention 2004 13 11 1710 1716
182. Sabatino L., Casamassimi A., Peluso G., A novel peroxisome proliferator-activated receptor γ isoform with dominant negative activity generated by alternative splicing Journal of Biological Chemistry 2005 280 28 26517 26525
183. Fiatte C., Huin C., Bertin I., Genetic analysis of peroxisome proliferator-activated receptor γ 1 splice variants in human colorectal cell lines International Journal of Oncology 2006 29 6 1601 1610
184. Kroll T. G., Sarraf P., Pecciarini L., P A X 8-PPARγ1 fusion oncogene in human thyroid carcinoma (Science (August 25) (1357)) Science 2000 289 5484 1357 1360
185. Watkins G., Douglas-Jones A., Mansel R. E., Jiang W. G., The localisation and reduction of nuclear staining of PPAR γ and PGC-1 in human breast cancer Oncology Reports 2004 12 2 483 488
186. Feilchenfeldt J., Bründler M.-A., Soravia C., Tötsch M., Meier C. A.
187. Khanim F. L., Gommersall L. M., Wood V. H. J., Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells Oncogene 2004 23 40 6712 6725
188. Chang T.-H., Szabo E., Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor- γ and inhibitors of histone deacetylase in adenocarcinoma of the lung Clinical Cancer Research 2002 8 4 1206 1212
189. Annicotte J.-S., Iankova I., Miard S., Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer Molecular and Cellular Biology 2006 26 20 7561 7574
190. Lal A., Lash A. E., Altschul S. F., A public database for gene expression in human cancers Cancer Research 1999 59 21 5403 5407
191. Fu M., Rao M., Bouras T., Cyclin D1 inhibits peroxisome proliferator-activated receptor γ -mediated adipogenesis through histone deacetylase recruitment Journal of Biological Chemistry 2005 280 17 16934 16941
192. Bonofiglio D., Gabriele S., Aquila S., Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells Clinical Cancer Research 2005 11 17 6139 6147
193. Yuri M., Sasahira T., Nakai K., Ishimaru S., Ohmori H., Kuniyasu H.
194. Gustafsson A., Hansson E., Kressner U., EP 1-4 subtype, COX and PPAR γ receptor expression in colorectal cancer in prediction of disease-specific mortality International Journal of Cancer 2007 121 2 232 240
195. Byrns M. C., Steckelbroeck S., Penning T. M.
196. Fung K.-M., Samara E. N. S., Wong C., Increased expression of type 2 3 α -hydroxysteroid dehydrogenase/type 5 17 β -hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma Endocrine-Related Cancer 2006 13 1 169 180
197. Lovering A. L., Ride J. P., Bunce C. M., Desmond J. C., Cummings S. M., White S. A.
198. Desmond J. C., Mountford J. C., Drayson M. T., The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs Cancer Research 2003 63 2 505 512
199. Matsuura K., Shiraishi H., Hara A.
200. Hursting S. D.
201. Evans R. M., The nuclear receptor superfamily: a rosetta stone for physiology Molecular Endocrinology 2005 19 6 1429 1438
202. Mitro N., Mak P. A., Vargas L., The nuclear receptor LXR is a glucose sensor Nature 2007 445 7124 219 223
203. Rodgers J. T., Lerin C., Haas W., Gygi S. P., Spiegelman B. M., Puigserver P.
204. Vanamala J., Glagolenko A., Yang P., Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPAR δ / PGE2 and elevation of PGE3 Carcinogenesis 2008 29 4 790 796
205. Kohno H.
206. Kohno H.
207. Stoll B. A., n -3 Fatty acids and lipid peroxidation in breast cancer inhibition British Journal of Nutrition 2002 87 3 193 198
208. Teresi R. E., Shaiu C.-W., Chen C.-S., Chatterjee V. K., Waite K. A., Eng C.
209. Doll R.
210. Govindarajan R.
211. Müller M.
212. Sanderson L. M., de Groot P. J., Hooiveld G. J., Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics PLoS ONE 2008 3 2 e1681
213. Zmuda J. M.
214. Carlberg C.
215. Hornberg J. J.
216. McCarty M. F., Activation of PPAR γ may mediate a portion of the anticancer activity of conjugated linoleic acid Medical Hypotheses 2000 55 3 187 188
217. Armoni M., Harel C., Karnieli E.
218. Nunn A. V. W.
219. Warburg O., On the origin of cancer cells Science 1956 123 3191 309 314
220. Cuezva J. M., Krajewska M., de Heredia M. L., The bioenergetic signature of cancer: a marker of tumor progression Cancer Research 2002 62 22 6674 6681
221. Ramanathan A., Wang C., Schreiber S. L.
222. Schulz T. J., Thierbach R., Voigt A., Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited Journal of Biological Chemistry 2006 281 2 977 981
223. Tayek J. A., A review of cancer cachexia and abnormal glucose metabolism in humans with cancer Journal of the American College of Nutrition 1992 11 4 445 456
224. Bassaganya-Riera J.
225. Sporn M. B.